14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FBT vs FXH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, First Trust NYSE Arca Biotechnology Index Fund (FBT) is the stronger overall head-to-head candidate over First Trust Health Care AlphaDEX Fund (FXH) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). FBT carries a Unified Composite Score of 50.3/100 (HOLD) at $267.86 (N/M Forward P/E, N/A operating margin), whereas FXH carries 48.7/100 (HOLD) at $136.68 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FBT vs FXH. Trailing 12-month operating profitability (FBT N/A vs FXH N/A) and valuation multiples (FBT N/M vs FXH N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ FBT vs FXH Key Questions & Quantitative Answers
As of Nov 16, 2026, First Trust NYSE Arca Biotechnology Index Fund (FBT) is the stronger overall head-to-head candidate over First Trust Health Care AlphaDEX Fund (FXH) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). FBT carries a Unified Composite Score of 50.3/100 (HOLD) at $267.86 (N/M Forward P/E, N/A operating margin), whereas FXH carries 48.7/100 (HOLD) at $136.68 (N/M Forward P/E, N/A operating margin). Technically, FBT sits in a Neutral phase (RSI 48.9, UNCLASSIFIED options structure) and FXH sits in a Markup phase (RSI 52.7, UNCLASSIFIED options structure).
FBT and FXH split Growth & Scale metrics: FBT posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with FXH at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, FBT generates N/A in USD-normalized revenue versus N/A for FXH. In operating R&D and SG&A reinvestment, FBT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FXH.
FBT and FXH trade at balanced relative valuation multiples. FBT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas FXH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FBT (N/A ROE) versus FXH (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, FBT carries 28.0% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.79β · 27% Vol realized risk). By comparison, FXH carries 22.8% implied volatility (85th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.57β · 25% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.